Biology Faculty Articles
Title
The Reversible Formation of Cysteine Sulfenic Acid Promotes B-cell Activation and Proliferation
Document Type
Article
Publication Date
8-2012
Publication Title
European Journal of Immunology
Keywords
B-cell activation, B-cell proliferation, Cysteine sulfenic acid, Reactive oxygen intermediates (ROIs)
ISSN
0014-2980
Volume
42
Issue/No.
8
First Page
2152
Last Page
2164
Abstract
B-cell receptor (BCR) ligation generates reactive oxygen intermediates (ROIs) that play a role in cellular responses. Although ROIs can oxidize all macromolecules, it was unclear which modifications control B-cell responses. In this study, we demonstrate the importance of the first oxidation product of cysteine, sulfenic acid, and its reversible formation in B-cell activation. Upon BCR crosslinking, B cells increase ROI levels with maximal production occurring within 15 min. Increased ROIs preceded elevated cysteine sulfenic acid, which localized to the cytoplasm and nucleus. Analysis of individual proteins revealed that the protein tyrosine phosphatases (PTPs) SHP-1, SHP-2, and PTEN, as well as actin, were modified to sulfenic acid following BCR ligation. Additionally, we used 5,5-dimethyl-1,3-cyclohexanedione (dimedone), a compound that covalently reacts with sulfenic acid to prevent its further oxidation or reduction, to determine the role of reversible cysteine sulfenic acid formation in regulating B-cell responses. Dimedone incubation resulted in a concentration-dependent block in anti-IgM-induced cell division, accompanied by a failure to induce capacitative calcium entry (CCE), and maintain tyrosine phosphorylation. These studies illustrate that reversible cysteine sulfenic acid formation is a mechanism by which B cells modulate pathways critical for activation and proliferation.
NSUWorks Citation
Crump, Katie E.; Daniel G. Juneau; Leslie B. Poole; Karen M. Haas; and Jason M. Grayson. 2012. "The Reversible Formation of Cysteine Sulfenic Acid Promotes B-cell Activation and Proliferation." European Journal of Immunology 42, (8): 2152-2164. doi:10.1002/eji.201142289.
DOI
10.1002/eji.201142289